LY-2584702 (free base)
LY-2584702 free base is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
Product Specifications
CAS Number
[1082949-67-4]
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
Ribosomal S6 Kinase (RSK)
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY-2584702-free-base.html
Purity
99.56
Solubility
DMSO : ≥ 4.5 mg/mL
Smiles
CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3
Molecular Formula
C21H19F4N7
Molecular Weight
445.42
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501
References & Citations
[1]Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50 (5) :867-75.|[2]Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75 (1) :40-50.|[3]Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12 (8) :e0182891.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
P70S6K
Citation 01
Harvard Medical School LINCS LIBRARY|Dev Cell. 2025 Nov 27:S1534-5807 (25) 00691-4.|Hepatology. 2023 May 1;77 (5) :1580-1592.|Immunity. 2021 Sep 14;54 (9) :2042-2056.e8.|Pharmacol Res. 2021 Oct 4;105871.|Theranostics. 2022 Jan 1;12 (3) :1204-1219.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items